Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
4.550
-0.510 (-10.08%)
Nov 5, 2026, 4:00 PM EST - Market closed
Entrada Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Entrada Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $19. The average 1-year stock price forecast is 317.58% higher than the current stock price, while the lowest is $11 (+141.76%) and the highest is $25 (+449.45%).
Price Target: $19 (+317.58%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Entrada Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Buy Maintains $11 → $10 | Buy | Maintains | $11 → $10 | +119.78% | Nov 5, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Oct 19, 2026 |
| Evercore ISI | Evercore ISI | Buy Maintains $25 | Buy | Maintains | $25 | +449.45% | Oct 16, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $23 | Buy | Reiterates | $23 | +405.49% | Sep 3, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 5, 2026 |
Financial Forecast
Revenue This Year
7.95M
from 25.42M
Decreased by -68.73%
Revenue Next Year
20.43M
from 7.95M
Increased by 156.96%
EPS This Year
-3.93
from -3.47
EPS Next Year
-3.24
from -3.93
EPS and Forward PE are based on non-GAAP adjusted numbers.